All In Biotech

Drug Trial Radar · NCT02285140

Prevention of Infections in Cardiac Surgery

Prevention of Infections in Cardiac Surgery: a Cluster-randomized Factorial Cross-over Trial

Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 5,989 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

5,989

Actual

Start

Apr 2015

Primary completion

Mar 10, 2025

Study completion Mar 10, 2025

Sponsor

Lead sponsor
Hamilton Health Sciences CorporationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Physicians' Services Incorporated Foundation
First posted
Nov 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Factorial
Masking
Single (outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There is clinical equipoise about the question of whether antibiotic prophylaxis should be given for a short period or an extended period of time as reflected by inconsistencies in major guidelines, current practices at Canadian centers, and as concluded in the three systematic reviews. There also is clinical equipoise on whether the addition of vancomycin to routine cefazolin prophylaxis can further reduce s-SSI rates. A short duration of combined antimicrobial prophylaxis can reduce side effects of exposure to antimicrobials such as infections with C. difficile or emergence of resistance, but may also reduce the incidence of s-SSIs. The objective of the eventual full scale study is to determine whether adding vancomycin to cefazolin can reduce SSIs as well as whether short-term prophylaxis is as effective as long-term prophylaxis. The rationale to conduct the proposed pilot study is to assess the feasibility to conduct this factorial cluster randomized cross-over trial, the adherence to the study protocol at each pilot site, the length of time to fill out the case report forms, and to get reliable estimates of event rates for sample size calculation for the main study

Conditions

  • Thoracic Surgery
  • Antibiotic Prophylaxis

Interventions

  • CefazolinDrug

    administration as outlined

  • VancomycinDrug

    administration as outlined

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients receiving antibiotics according to study protocolTime frame: 3 months post-surgery
  2. Proportion of patients with complete follow-up, i.e. up to 90 days or death; goal >95%Time frame: 3 months post-surgery
  3. Agreement of blinded outcome assessment based on information from the case report formTime frame: 3 months post-surgery

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Jewish Hospital

    Montreal, Quebec, Canada

  • University of Sherbrook

    Sherbrook, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.